203 related articles for article (PubMed ID: 32861208)
1. The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions.
Gebhardt C; Ascierto P; Atkinson V; Corrie P; Dummer R; Schadendorf D
Eur J Cancer; 2020 Oct; 138():68-76. PubMed ID: 32861208
[TBL] [Abstract][Full Text] [Related]
2. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
Valpione S; Carlino MS; Mangana J; Mooradian MJ; McArthur G; Schadendorf D; Hauschild A; Menzies AM; Arance A; Ascierto PA; Di Giacomo A; de Rosa F; Larkin J; Park JJ; Goldinger SM; Sullivan RJ; Xu W; Livingstone E; Weichenthal M; Rai R; Gaba L; Long GV; Lorigan P
Eur J Cancer; 2018 Mar; 91():116-124. PubMed ID: 29360604
[TBL] [Abstract][Full Text] [Related]
3. BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma.
Cybulska-Stopa B; Rogala P; Czarnecka AM; Galus Ł; Dziura R; Rajczykowski M; Kubiatowski T; Wiśniewska M; Gęga-Czarnota A; Teterycz P; Ziobro M; Suwiński R; Mackiewicz J; Rutkowski P
Melanoma Res; 2020 Oct; 30(5):465-471. PubMed ID: 32221131
[TBL] [Abstract][Full Text] [Related]
4. The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients.
Zaremba A; Eggermont AMM; Robert C; Dummer R; Ugurel S; Livingstone E; Ascierto PA; Long GV; Schadendorf D; Zimmer L
Eur J Cancer; 2021 Sep; 155():268-280. PubMed ID: 34392069
[TBL] [Abstract][Full Text] [Related]
5. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
[TBL] [Abstract][Full Text] [Related]
6. BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
Van Not OJ; van den Eertwegh AJM; Haanen JB; van Rijn RS; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; de Groot JWWB; Hospers GAP; Kapiteijn E; Bloem M; Piersma D; Stevense-den Boer M; Verheijden RJ; van der Veldt AAM; Wouters MWJM; Blokx WAM; Suijkerbuijk KPM
Cancer; 2024 May; 130(9):1673-1683. PubMed ID: 38198485
[TBL] [Abstract][Full Text] [Related]
7. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings.
Broman KK; Dossett LA; Sun J; Eroglu Z; Zager JS
Expert Opin Drug Saf; 2019 May; 18(5):381-392. PubMed ID: 30977681
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
[TBL] [Abstract][Full Text] [Related]
9. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
10. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
[TBL] [Abstract][Full Text] [Related]
11. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
12. ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC).
Alves-Fernandes DK; Oliveira ÉA; Faião-Flores F; Alicea-Rebecca G; Weeraratna AT; Smalley KSM; Barros SBM; Maria-Engler SS
Pharmacol Res; 2019 Mar; 141():63-72. PubMed ID: 30550954
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of BRAF-mutated metastatic melanoma].
Boyles TB; Svane IM; Bastholt L; Schmidt H
Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592869
[TBL] [Abstract][Full Text] [Related]
14. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
[TBL] [Abstract][Full Text] [Related]
15. BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes.
Lee J; Ahmed T; Maurichi A; Di Guardo L; Stagno AM; Warburton L; Taylor AM; Livingstone E; Rehman S; Khattak A; Kahler KC; Vanella V; Atkinson V; Millward M; Schadendorf D; Johnson DB; Ascierto PA; Hauschild A; Lo SN; Long GV; Menzies AM; Carlino MS
Eur J Cancer; 2023 Jan; 179():87-97. PubMed ID: 36509002
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
Taylor AM; McKeown J; Dimitriou F; Jacques SK; Zimmer L; Allayous C; Yeoh HL; Haydon A; Ressler JM; Galea C; Woodford R; Kahler K; Hauschild A; Festino L; Hoeller C; Schwarze JK; Neyns B; Wicky A; Michielin O; Placzke J; Rutkowski P; Johnson DB; Lebbe C; Dummer R; Ascierto PA; Lo S; Long GV; Carlino MS; Menzies AM
Eur J Cancer; 2024 Mar; 199():113561. PubMed ID: 38278009
[TBL] [Abstract][Full Text] [Related]
17. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
Moser JC; Chen D; Hu-Lieskovan S; Grossmann KF; Patel S; Colonna SV; Ying J; Hyngstrom JR
Cancer Med; 2019 Dec; 8(18):7637-7643. PubMed ID: 31677253
[TBL] [Abstract][Full Text] [Related]
18. Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: experience from an Italian skin cancer unit.
Quaglino P; Fava P; Brizio M; Marra E; Rubatto M; Merli M; Tonella L; Ribero S; Fierro MT
Future Oncol; 2021 Mar; 17(7):759-761. PubMed ID: 33533662
[No Abstract] [Full Text] [Related]
19. Therapeutic targets in melanoma: map kinase pathway.
Haluska FG; Ibrahim N
Curr Oncol Rep; 2006 Sep; 8(5):400-5. PubMed ID: 16901402
[TBL] [Abstract][Full Text] [Related]
20. Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.
Cohen JV; Sullivan RJ
Clin Cancer Res; 2019 Oct; 25(19):5735-5742. PubMed ID: 30992297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
